About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, November 22nd, 2017

The QualityStocks
Daily Stock List


Northstar Electronics, Inc. (NEIK)

Front Page Stocks, Stockhouse, MarketWatch, Marketwired, and OTC Watch reported on Northstar Electronics, Inc. (NEIK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Northstar Electronics, Inc. is working in the aviation, defense, and marine industries. The Company has an extensive history of developing and manufacturing defense and commercial electronic and mechanical systems. Northstar formed in the late 1990’s. It carried out design and manufacturing contracts for different divisions of Lockheed Martin Corp. In addition, it designed, manufactured, and sold its own sonar-based system to commercial customers. Northstar Electronics lists on the OTC Markets’ OTCQB. The Company has its corporate office in Virginia Beach, Virginia.

Northstar Electronics has moved towards making and selling its own independent systems, since the termination of the above contracts. Northstar Electronics is now undergoing restructuring to go forward with a renewed emphasis on the development of a new aviation business as well as carry out work to develop unique sonar systems.

Northstar Electronics earlier stated that its subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), is working to acquire the global rights to a “Turbo-Prop” single engine industrial airplane from an international leader in the aerospace industry. The timeline for the final agreement with the subsidiary company, which owns the rights to the airplane, has been extended.

Dr. Wilson Russell, Northstar Electronics’ Chief Executive Officer, said, “Although the timeline to an agreement has been extended, the potential resulting benefits are highly significant to Northstar. It also means that we would likely have the support of the parent company for up to five years going forward. "

The main applications for the airplane are in “Agriculture and Rapid Response Forest Fire Fighting.” Northstar Sealand Enterprises is continuing its assessment of the “Cloud Seeding” market. Company Management believes the new design features of the NSEL airplane will rapidly lead to it being a leader in its class.

Upon the signing of the airplane “Rights Acquisition Agreement”, Northstar Sealand Enterprises’ intention is to launch its plans to start the actions leading to manufacturing the airplane and marketing it around the world.

Subsidiary Northstar Sealand Enterprises registered in 2014. It is jointly owned by Northstar Electronics and Sealand Aviation Ltd.  Both companies have numerous years of experience in working with certified commercial aircraft and government military contracts.

Northstar Sealand Enterprises is finalizing arrangements to assemble, certify, manufacture, service, repair, and market the new turboprop single engine commercial aircraft in Canada, for the global market, beginning with the North, South, and Central American markets at first. Work is moving ahead on the prototype aircraft.

Northstar Electronics, Inc. (NEIK), closed Wednesday's trading session at $0.013, down 5.80%, on 40,050 volume with 4 trades. The average volume for the last 60 days is 62,568 and the stock's 52-week low/high is $0.0078/$0.0349.

Blow & Drive Interlock Corp. (BDIC)

TradingView, Equities, MarketWatch, YCharts, and News to Watch reported on Blow & Drive Interlock Corp. (BDIC), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Blow & Drive Interlock Corp. provides automotive and criminal offender monitoring security products. The Company has its state‐of‐the‐art ignition interlock device: BDI-747. This device is approved and available in eight states for evidentiary and preliminary screening use. Fundamentally, Blow & Drive Interlock is an offender monitoring and police-grade alcohol detection device manufacturing and offender monitoring business.

The Company lists on OTC Markets Group’s OTCQB. Blow & Drive Interlock is headquartered in Los Angeles, California.

Interlocks are required for use by DUI or DWI (Driving Under The Influence or Driving While Intoxicated) offenders. This is as part of their mandatory court or motor vehicle department program.

Blow & Drive Interlock’s goal is to have the BDI-747 available to customers across the United States. Furthermore, the Company continues to do research and development (R&D) on the next stage of offender monitoring. It believes this will be Smartphone enabled monitoring applications (apps) that could decrease or eliminate the need for ankle bracelets or hand-held breathalyzers.

Blow & Drive Interlock’s BDI-747 is an ignition interlock device, breath-alcohol testing device roughly the size of a Smartphone. The ignition interlock device requires the driver to exhale into the device before starting the vehicle. The device will prevent the vehicle from starting if the driver's blood-alcohol content surpasses a predetermined set level.

The BDI-747 can record BAC levels. It provides 2-way communication, GPS location technology, and image technology. In addition, the BDI-747 is wireless.

At the beginning of November, Blow & Drive Interlock announced its newest products to go to market in Early 2018. The Company unveiled and demonstrated its Home Alcohol Monitoring Device.

The Handheld device has a camera and GPS/WIFI & live streaming. It allows those in Judicial and Probation departments to monitor offenders who are required to stay sober from alcohol while on probation.

Blow & Drive Interlock also unveiled its 4G LTE Live-Streaming Video Body Worn Camera for Law Enforcement. With the Company’s 4G LTE Live-Streaming Video Body Worn Camera, Law Enforcement Personnel on the scene can transmit a live feed from their body cameras to headquarters. This permits police decision makers’ access to real time information concerning what each officer is seeing.

The body camera weighs approximately 210g. It provides up to 32 GB of memory and 5-megapixel recording. Moreover, it offers infrared technology for night recording, numerous resolution settings, pre-and post-recording capabilities, and many more features. These are to assist officers in obtaining high quality video recording.

Blow & Drive Interlock Corp. (BDIC), closed Wednesday's trading session at $0.22, even for the day. The average volume for the last 60 days is 2,053 and the stock's 52-week low/high is $0.10/$0.65.

Canabo Medical, Inc. (CAMDF)

InvestorsHub, Stockhouse, MarketWatch, Daily Marijuana Observer, Barchart, and OTC Markets reported on Canabo Medical, Inc. (CAMDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Canabo Medical, Inc. wholly owns and operates Cannabinoid Medical Clinics, or CMClinics. These are Canada's largest physician led referral-only clinics for medical cannabis. Clinics operated by the Company are staffed by physicians and qualified health care practitioners. They have specific training to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress. Established in 2014, Canabo Medical is based in Vancouver, British Columbia. The Company lists on the OTCQB.

The Company operates referral-only medical clinics. These are devoted to evaluating the suitability of prescribing and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses.

The commitment of CMClinics is to helping patients find effective treatment for chronic and serious conditions via the use of prescription cannabinoids and medical marijuana. The commitment of CMClinics is also on educating patients, physicians, and the community, and advancing research in the medical marijuana field.

There is no fee to see a physician at a CMClinic. A CMClinic does require a referral from one’s family physician or specialist. Patients referred to a CMClinic will undergo an initial medical examination. This is to evaluate their needs and suitability for prescription cannabinoids or medical marijuana.

This past June, Canabo Medical announced it opened its second clinic in the Province of Nova Scotia for a total of 22 clinics and partner clinics across the nation. The new clinic is located in Wolfville, Nova Scotia.

In October, Canabo Medical reported that it will receive a $310,000.00 Research Grant to conduct a study on the reduction of opioids for patients’ prescribed medical cannabis. This study will involve 1,000 patients now using opioids to manage chronic pain. The study will examine whether the use of opioids among patients experiencing chronic pain increase or decrease following the prescription of medical cannabis.

In addition, in October, Canabo Medical announced that it launched its Self-Referral Sleep Aid program. This program is a first of its kind in Canada. Patients with sleep issues can now schedule a medical clinic appointment directly with no prior requirement for a physician's referral.

Last week, Canabo Medical reported that Company Management determined Canabo is cash flow positive for Q4 ended October 31, 2017. Company Management anticipates a continued positive outlook for Q1 of fiscal 2018.

Canabo physicians saw greater than 3,900 new patients in Q4. Canabo clinics handled more than 9,800 new and recheck patients during Q4. This represents a 95 percent increase over the same period the year prior.

Canabo is operating clinics in separate clinic locations throughout Canada. More than 96 percent of new Canabo patients registered with its research partners. In addition, there are more than 80 Physicians trained under the Canabo proprietary training program for prescribing medical Cannabis and another 60 physicians are waiting to join the Company’s team.

Canabo Medical, Inc. (CAMDF), closed Wednesday's trading session at $0.5296, up 27.37%, on 13,042 volume with 16 trades. The average volume for the last 60 days is 7,835 and the stock's 52-week low/high is $0.246/$1.00.

Evans Brewing Company, Inc. (ALES)

MarketWatch reported on Evans Brewing Company, Inc. (ALES), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Evans Brewing Company, Inc. is a producer of award-winning craft beers and the owner of The Public House restaurant and tap room. The Company brews and distributes premium craft brands that have been honored with over 20 international awards. It supplies restaurants, retailers, and beer drinkers throughout seven western states. Evans Brewing has its brewery in Irvine, California. The Company lists on the OTCQB.

Evans Brewing Company has produced the first beer in its small batch brewing system - two variations of its Original Pilsner. The expectation is that these will be available at The Public House. The variations of The Original include one using German dry hops and another using American dry hops.

Evans Brewing has released "Stout at the Devil," a Russian Imperial Stout. This particular product is in kegs. However, it will join Pollen Nation, KrHOPen IPA, Chocolatte Chocolate Porter and Oaklore Brown Ale as a year-round offering.

Evans Brewing Company operates the oldest brewery in Orange County, California. Furthermore, it offers its ales and lagers, along with a complete Gastropub food menu at its restaurant and tap room, The Public House by Evans Brewing Company.

The Public House is in the Soco District of downtown Fullerton, California. The eatery features a unique pub food menu, made in its scratch kitchen. This complements the Company’s craft beers. The space features dark-wood floors, exposed brick, and artwork. This highlights the brand’s Orange County and California roots.

The Public House offers live music. This includes jazz and an extensive selection of different genres.

Evans Brewing signed a ten-year lease in 2016 for its second Public House location next to The Triangle in Costa Mesa, California. The Triangle is one of Orange County's premier dining and entertainment destinations.

The second Public House by Evans Brewing Company is at 110 Broadway, Costa Mesa. This is close to several popular bars and restaurants along Newport Boulevard near the Costa Mesa and Newport Beach border.

Evans Brewing Company announced this past January that it signed a ten-year lease for another Public House location at the Bella Terra Mall in Huntington Beach, California. The Bella Terra Mall is one of the premier dining and entertainment destinations in the area.

Evans Brewing Company, Inc. (ALES), closed Wednesday's trading session at $0.55, even for the day. The average volume for the last 60 days is 1,171 and the stock's 52-week low/high is $0.418/$2.30.

NuLife Sciences, Inc. (NULF)

CNA Finance, Investors Hub, and MarketWatch reported on NuLife Sciences, Inc. (NULF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Established in 2013, NuLife Sciences, Inc. concentrates on advancing human organ transplant technology and medical research. A biomedical enterprise, the Company has a patent protected, innovative, proprietary method (the NuLife Technique). It centers on medical research and technology that has the potential to address major unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants.

The Company formerly went by the name SmooFi, Inc. It changed its corporate name to NuLife Sciences, Inc. in December 2016. NuLife Sciences is headquartered in Newport Beach, California. The Company operates through two wholly-owned subsidiaries, NuLife Medical and NuLife BioMed.

NuLife Sciences is focusing on an inventive, patented, proprietary method, the above-mentioned 'NuLife Technique’. The Company said that this technique could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs in human organ transplant. With the Discovery phase completed, the Company’s intention is to enter a Preclinical phase involving animal experiments in collaboration with Florida International University and Nova Southeastern University.

The NuLife Technique was developed through 15 years of dedicated research. The result has been numerous breakthroughs in hematopoietic research and transplant techniques. The objective of the research was to address the issues of organ compatibility and the need for anti-rejection drugs in the donor

NuLife’s technique is versatile. Additionally, it is suitable for an array of clinical indications. NuLife Sciences has extensive patent and Intellectual Property (IP) protections in place.

NuLife Sciences, via its wholly-owned subsidiary, NuLife BioMed, previously announced that it moved into space at Nova Southeastern University's (NSU) prestigious Center for Collaborative Research (CCR). This is where it will conduct research on the NuLife Technique. NuLife leased 350 square feet of space in the new, state-of-the-art facility. This facility offers collaboration with NSU's expert researchers and access to the CCR's sophisticated equipment, technology, and also laboratories.

NuLife Sciences, via NuLife BioMed, announced this past August that it began a pre-clinical trial on the NuLife Technique. The trial started on August 8, 2017 at Florida International University. The trial will evaluate the NuLife process in an autologous setting, meaning an organ is removed from and transplanted back to the same donor. The aim of the study is to prove that the NuLife Technique is viable.

NuLife Sciences, through NuLife Medical, announced in September plans to commercialize its lead compound, lyophilized Cytokine Concentrated Plasma (lyoCCP) in Ecuador. The lyoCCP product is produced using the NuLife Technique. The proprietary product has shown notable results in aiding the healing of wounds, which have been resistant to closure with traditional methods. An observational study took place earlier in 2017, showing impressive results in ten subjects. A larger study is planned.

Recently, NuLife Sciences announced the signing of a Letter of Intent (LOI) to undertake a formal merger with Ensysce Biosciences of San Diego, California. Ensysce Biosciences is a clinical stage company with delivery platforms for small and large molecule therapies. Its BIO-MD™ is a prodrug delivery platform. This platform provides abuse deterrence to a long list of prescription drugs, including opioid products.

NuLife Sciences, Inc. (NULF), closed Wednesday's trading session at $0.175, even for the day. The average volume for the last 60 days is 5,566 and the stock's 52-week low/high is $0.151/$1.50.

Towerstream Corp. (TWER)

Investing Futures, MicroCapDaily, Investment Contrarians, Jason Bond, KingPennyStocks, Broad Street, BullRally, BUYINS.NET, ChartPoppers, CoolPennyStocks, Damn Good Penny Picks, Epic Stock Picks, Hit and Run Candle Sticks, HotOTC, MadPennyStocks, Marketbeat, MarketClub Analysis, Money Morning, OTCBB Journal, OTCMagic, Penny Picks, Penny Stock Prodigy, PennyInvest, and PennyOmega reported earlier on Towerstream Corp. (TWER), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Towerstream Corp. is a leading Fixed-Wireless Fiber Alternative company headquartered in Middletown, Rhode Island. It delivers high-speed Internet access to businesses. Together with its subsidiaries, Towerstream provides fixed wireless broadband services and delivers access over a wireless network transmitting over regulated and unregulated radio spectrum to commercial customers in the U.S. Towerstream’s shares trade on the OTC Markets’ OTCQB.

A last-mile facilities-based provider, Towerstream owns its entire network. The Company totally bypasses the local exchange carrier and cable providers. Towerstream’s solution to businesses either complements or replaces existing Internet connections.

The Company provides property managers, building owners, and their commercial tenants a redundant and reliable dense urban network. This network directly connects to the Company’s fiber backbone.

The Company provides broadband services in twelve urban markets. These include New York City, Boston, Los Angeles, Chicago, Philadelphia, the San Francisco Bay area, Miami, Seattle, Dallas-Fort Worth, Houston, Las Vegas-Reno, and the greater Providence area.

Towerstream has built 175 Major Points of Presence (POPs). The Company positions its POPs on the tops of buildings. These include the Empire State Building and Met Life in New York, New York; the Hancock Building in Chicago, Illinois; and the AON Building in Los Angeles, California.

Towerstream has its Single Tenant Internet Solution. This solution is for customers not in On-Net buildings. The Single Tenant Internet Solution provides primary and back-up dedicated internet access as a faster and less expensive alternative to fiber.

The Company’s On-Net Service provides businesses within its continually increasing portfolio of On-Net buildings with dedicated and symmetrical Internet connectivity. On-Net refers to the extensive number of buildings in the Company’s 12 coverage markets currently lit for On-Net Business Internet Service.

Towerstream selects the qualified commercial buildings in its markets to be able to provide high-capacity bandwidth at considerable savings. Towerstream’s objective is to highly penetrate each On-Net Building.

Last week, Towerstream announced financial results for Q3 ended September 30, 2017. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) of $340,000 rose 38 percent in Q3 of 2017 versus Q2 of 2017.

Q3 revenues of $6,555,000 increased sequentially quarter over quarter. Average revenue per user (ARPU) for new sales contracts was $579 for Q3 of 2017. This represents a 32 percent increase from Q3 of 2016. Churn was reduced to 1.26 percent in Q3 of 2017 from 2.02 percent in Q3 of 2016.

Towerstream Corp. (TWER), closed Wednesday's trading session at $4.20, down 8.50%, on 2,065 volume with 18 trades. The average volume for the last 60 days is 909 and the stock's 52-week low/high is $0.0645/$6.50.

ProGreen US, Inc. (PGUS)

Promotion Stock Secrets and Penny Stock Prodigy reported previously on ProGreen US, Inc. (PGUS), and we report on the Company today, here at the QualityStocks Daily Newsletter.

ProGreen US, Inc. engages primarily with investments in agricultural and real estate projects in Baja California, Mexico. It is focusing on intensifying its property investments in Baja California, Mexico, via its joint venture (JV) partnership with Inmobiliaria Contel, as well as through its subsidiary Procon Baja JV. Listed on the OTC Markets’ OTCQB, ProGreen US is based in San Diego, California.

Regarding the Company’s Baja Project, it entered into a JV with a Mexican landowner, Inmobiliaria Contel and has jointly created Pro Baja, the Company’s newest JV with ProGreen owning 51 percent and Inmobiliaria Contel 49 percent. ProGreen has established an office location in Ensenada that will serve as headquarters for all of its activities in Baja California. Procon and Contel will operate from this location.

Procon has acquired 5,100 acres of land with 4.7 miles of oceanfront on the Bay of El Rosario, for which a master plan is being drawn for the development of a very large, completely green, global vacation and retirement community called "CieloMar." Contel is currently active in the high margin produce industry, growing crops for exporters to the U.S. market, with an abundance of land available for expansion under its JV partnership.

ProGreen US has completed development of the first tract of land, which consists of roughly 300 acres. Of this, some 100 usable acres have been cleared.

ProGreen US earlier signed another agreement for a further 1,900 acres (500-800 usable for farming), and a 3-year option for 11,500 acres (1000-2500 usable for farming). This land, once developed and prepared, will be offered for long term lease (10-15 years), with the JV holding the title.

At the end of October, ProGreen said that a video podcast of its massive Baja California Real Estate project "CieloMar" has been published on the Company's website. The first video podcast presents an outline of some of the development's major amenities. These amenities include a private airport, a commercial and industrial area, a yacht marina, and three golf courses.

This month, ProGreen US announced that it has started the process of obtaining the certification of its agriculture operations in Baja California, for direct export, so that the Company can sell the ProGreen Farms™ produce directly to prospective United States buyers.

ProGreen is continuing with this year's chili pepper harvest. In addition, it has started the planning phase for next year's operations and is currently moving ahead planning with some of the first steps. Moreover, ProGreen is in advanced discussions with a market leading U.S. food processor, for direct sales of produce from the ProGreen Farms™ operations in Baja, California.

ProGreen US, Inc. (PGUS), closed Wednesday's trading session at $0.0119, up 6.40%, on 218,550 volume with 11 trades. The average volume for the last 60 days is 795,992 and the stock's 52-week low/high is $0.0071/$0.03.


The QualityStocks
Company Corner


First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.77, up 29.19%, on 568,191 volume with 266 trades. The stock’s average daily volume over the past 60 days is 64,763, and its 52-week low/high is $0.3148/$0.67.

First Cobalt Corp. (TSX-V:FCC) (OTCQB:FTSSF) is pleased to announce shareholders of CobalTech Mining Inc. (TSX-V:CSK) have approved the merger with First Cobalt, with 95% of votes cast in favour. Trent Mell, President & Chief Executive Officer, commented: “We now have approval from CobalTech and Cobalt One shareholders to finalize the three-way merger and we look forward to closing both transaction over the next 2 weeks. First Cobalt now controls approximately 45% of the prospective land in the Cobalt Camp. This historic mining camp has never seen the required land consolidation to permit district-scale exploration and we will remain very active in 2018.”

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, seeks to create the world's largest pure-play cobalt exploration and development company. The company's current focus is on its Greater Cobalt Project located in Silver Centre, Ontario. The company is also in the midst of a three-way merger with Cobalt One Ltd. and CobalTech Mining Inc. and on completion First Cobalt will control over 10,000 hectares of prospective land and 50 historic mining operations in the Cobalt Camp in Ontario, Canada, as well as a mill and a permitted refinery facility.

The merger agreements with Cobalt One Ltd. and CobalTech Mining Inc., announced earlier this year, will result in a combined land position of more than 10,000 hectares (nearly 25,000 acres) in the Cobalt Camp containing approximately 50 past cobalt/silver producers and working mines. Initial test results from a mineralogical assessment of sample material taken from various historical mines located throughout the Cobalt Camp show both cobalt-rich and silver-rich mineralization styles. Samples taken at the former Bellellen mine, located within the Greater Cobalt Project in Ontario, show high grade cobalt assays, prompting First Cobalt to increase its drilling program at that site.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world's current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

The company's clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

CobalTech Shareholders Approve Merger with First Cobalt

First Cobalt Reports 9.4% Cobalt Sample from Caswell Mine Prospecting Program

Cobalt One Shareholders Overwhelmingly Approve Merger with First Cobalt


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.13, up 20.34%, on 1,511,063 volume with 1,047 trades. The stock’s average daily volume over the past 60 days is 310,602 and its 52-week low/high is $0.6171/$1.25.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF), a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis and one of the earliest licensed Canadian medical marijuana producers. The publication, titled, "Outsized Demand in Canada's Cannabis Market Triggers Upswing in Smart Money Flowing North," highlights the surge of investment capital to Canada's licensed producers (LPs) ahead of the country's pending legalization of recreational marijuana. To view the full publication, visit: https://www.networknewswire.com/outsized-demand-canadas-cannabis-market-triggers-upswing-smart-money-flowing-north/

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

NetworkNewsWire Announces Publication on Investment Capital Pouring into Canada's Legal Cannabis Market

Outsized Demand in Canada’s Cannabis Market Triggers Upswing in Smart Money Flowing North

Coming Cannabis Recreational Demand in Canada Triggers Massive Investment


The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $0.51, up 2.00%, on 71,656 volume with 53 trades. The stock’s average daily volume over the past 60 days is 25,659, and its 52-week low/high is $0.49/$3.20.

EVIO, Inc. (OTCQB: EVIO), a life science company and leading provider of quality control testing and advisory services to the regulated cannabis industry, announced that it has been granted an expansion to its accreditations from the Oregon Environmental Laboratory Accreditation Program (ORELAP), a division of the Oregon Health Authority.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO Inc. Granted Expanded Accreditation to Test for Pesticides and Residual Solvents

EVIO, Inc. Expands Testing Services at its Northern California Laboratory

EVIO Labs Expands to Fifth Oregon Location

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.398, off by 1.49%, on 34,218 volume with 21 trades. The stock’s average daily volume over the past 60 days is 35,355 and its 52-week low/high is $0.171/$0.48.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP) announces that the scientists of its research arm, Cannevert Therapeutics Ltd. ("CTL") will be presenting their first peer-reviewed research of its cannabis strains targeting pain at the British Pharmacological Meeting (BPS) in London, UK from December 11-13, 2017.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Cannevert Scientists to Present Their First Peer-Reviewed Research at December’s Prestigious British Pharmacological Society Meeting in London, UK

Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is “One to Watch”

Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.42, off by 10.64%, on 73,955 volume with 14 trades. The stock’s average daily volume over the past 60 days is 35,655 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (OTC: ORHB), today provides a business update and announces a special warrant exercise price of $0.35 per warrant for all Series. Recent Corporate Highlights:

  • Signed a 5-year revenue agreement (http://nnw.fm/t97Fx) with a three-hospital system in Southern California, recognized as one of the "100 Great Hospitals in America" by Becker's Hospital Review.
  • Entered into an agreement with a US News & World Report Top 20 Medical School for a fully paid installation.
  • Secured the commitment of three additional hospitals; implementation details and dates forthcoming in a future press release.
  • Expanded our channels for revenue to include medical technology companies, as well as plans for product offerings to payors, pharmaceutical companies and government agencies.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. (ORHB) Provides 2017 Business Highlights and Sets Special Warrant Exercise Price

ORHub, Inc. (ORHB) Signs 5-year Revenue Agreement with Nationally Recognized "Top 100" Hospital

ORHub, Inc. (ORHB) Warrants Set to Expire on December 31, 2017

HighCom Global Security, Inc. (HCGS)

The QualityStocks Daily Newsletter would like to spotlight HighCom Global Security, Inc. (HCGS). Today, HighCom Global Security, Inc. closed trading at $0.02, up 23.46%, on 51,842 volume with 9 trade. The stock’s average daily volume over the past 60 days is 58,566 and its 52-week low/high is $0.006/$0.10.

HighCom Global Security, Inc. (HCGS) is a manufacturer and distributor of protective products for military and law enforcement personnel. The Corporation operates under two segments, BlastGard Defense Group and Highcom Security.

BlastGard is a blast mitigation specialist with proprietary material proven to effectively mitigate blasts and suppress fires resulting from explosions. The company's patented BlastWrap® technology acts as a "virtual tent" to effectively mitigate blast effects and suppress post-blast fires. This unique technology works by triggering physical and chemical processes to dissipate blast energy, thereby reducing the aftermath of acoustic and shock waves, peak overpressure, reflected peak overpressure, impulse and afterburn. The remaining, significantly reduced energy is transmitted at a slower, more sustainable level. Notably, BlastWrap does not dispense chemical extinguishants; uses neither alarms, sensors, nor an activation system; and is nontoxic and ecologically friendly.

Similarly, the company's BlastGard MTR trash receptacles dramatically reduce lethal threats posed by the detonation of an improvised explosive device (IED). Equipped with Triple Wall Technology, BlastGard MTR mitigates primary fragments, secondary fragments, mechanical effects (shock/blast pressure) and thermal effects (contact and radiation burn) from the fireball, after-burn and resultant post-blast fires.

BlastGard's primary market focus lies on providing blast effects mitigation solutions for customers operating in the commercial sector, military, law enforcement and government agencies. With a vision of being recognized as the leading provider of environmentally responsible solutions to protect lives and structures from the hazards associated with fire and explosions, the company is capable of addressing a wide array of industry applications spanning from fire suppression for naval vessels and merchant ships to protection of buildings against vehicle bombs.

This vision is supported by the ban of Halon extinguishing agents, as outlined in the Montreal protocol, which effectively establishes BlastWrap® as the only blast and fire suppression means available for most applications, including adaptation for underwater use.

The company's position at the head of the blast suppression market has helped BlastGard attain a number of government awards, including designation of its BlastWrap® product as a Qualified Anti-Terrorism Technology and placement on the "Approved Products List for Homeland Security." This designation was extended in early 2017, meaning that BlastWrap® is approved for use by the Department of Homeland Security under the SAFETY Act until November 2021.

HighCom Security, develops, tests, manufactures and distributes body armor and personal protective equipment, including more than two dozen NIJ (National Institute of Justice) compliant hard and soft armor products. Highcom Security has a 20-year history of producing quality armor with no operational failures and no recalls of its American made products.

Highcom Security was founded in 1997 and has produced close to 1 million pieces of armor for the Global community. The company is ISO 9001:2008 certified and the first company in the world to be BA 9000:2012 certified compliant.

For the past decade, Highcom Security has also been able to offer some of the largest armor manufacturers with private label/OEM hard armor solutions for end use by military and law enforcement agencies globally, a market reach obtained because of the company's reputation for innovative technology, exceptional customer service and superior quality performance. Disclaimer

HighCom Global Security, Inc. Blog

HighCom Global Security, Inc. News:

HighCom Global Security receives OTCQB approval

HighCom Global Security Provides Q2, FH 2017 Financial Update

HighCom Global Security Issues Update on Product Technology Advances

Blue Moon Zinc Corp. (TSX.V: MOON) (OTC: BMOOF)

The QualityStocks Daily Newsletter would like to spotlight Blue Moon Zinc Corp. (BMOOF). Today, Blue Moon Zinc Corp. closed trading at $0.0301, even for the day. The stock’s average daily volume over the past 60 days is 37,286 and its 52-week low/high is $0.008/$0.087.

Blue Moon Zinc Corp. (TSX.V: MOON) (OTC: BMOOF), a mineral exploration company, is focused on developing its advanced-stage, wholly owned Blue Moon zinc project in central California. The project sits within Mariposa County, an area of active mines and exploration projects since it was part of the California gold rush era. Blue Moon's 525 acres of mineral rights are assigned to patented and unpatented claims accessible by a gravel road off a nearby highway with main utility lines nearby.

The Blue Moon deposit is one of many located in the Foothills Massive Sulphide Belt in the Sierra Nevada Mountains of California. The property has a long history of exploration and saw small-scale mining during World War II. The current project, to be mined by underground methods, contains an estimated 3.70 million tons with a grade of 8.33% zinc equivalent for approximately 377 million pounds of zinc in the indicated category and another 4.09 million tons with a grade of 7.84% zinc equivalence for approximately 395 pounds of zinc in the inferred category. Significant bi-products of copper, silver and gold are also indicated. The deposit is open at depth and along strike with a high likelihood of expansion.

Current spot prices for zinc is approximately $1.40 per pound, which increases the potential returns of the Blue Moon project.

The historical database shows extensive plans to put the Blue Moon project into production, including several scoping and optimization studies. Past environmental work performed, along with an historical permit and reclamation plan approved for certain underground development, highlights past local county support for the project. These historical studies and permits are expected to help fast track the project's progress as they form an excellent base for the upcoming Preliminary Economic Assessment and later feasibility study.

Among the significant historical studies conducted is a 1998 metallurgical report that shows recovery rates of 95 percent for zinc and lead, 93 percent for copper, 65 percent for silver and 70 percent for gold (http://nnw.fm/U1ckE). The report indicates that simple processing methods will produce premium concentrates with easy separation of the economic minerals.

Blue Moon CEO Patrick McGrath, who has 20 years of experience in financing and executive roles in the junior mining public sector, is joined by a management team with successful track records in leading and participating in significant mineral discoveries with development-stage mining companies. The Blue Moon team also includes a member who permitted and built the Soledad mine in southern California in 2016 and a member who re-started the Mesquite mine in southern California. Local knowledge and know-how is key. The company also plans to engage a recognized third-party engineering firm to prepare a preliminary economic assessment report, expected for release in the first quarter of 2018, to demonstrate the economic viability of the Blue Moon mineral resources. Disclaimer

Blue Moon Zinc Corp. Blog

Blue Moon Zinc Corp. News:

NetworkNewsWire Releases Exclusive Audio Interview with Blue Moon Zinc Corp. (TSX.V: MOON) (OTC: BMOOF)

NetworkNewsWire Announces Publication Discussing the Favorable Outlook on Zinc

Blue Moon Announces Updated Mineral Resource Estimate


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(DRWIQ) +41.44%


Trader Power News
(CLNT) +59.55%


Wealth Insider Alert
(MARA) +53.53%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251